Encyclopedia of Signaling Molecules

2018 Edition
| Editors: Sangdun Choi


Reference work entry
DOI: https://doi.org/10.1007/978-3-319-67199-4_562


Historical Background

Mammalian VRK (vaccinia-related kinases) were originally identified as two human EST, VRK1 and VRK2, expressed in proliferating cell lines and regenerating liver. These EST have homology to the catalytic region of the B1R kinase of vaccinia virus (Nezu et al. 1997) that is expressed early in viral infection and is required for viral DNA replication. These VRK proteins were classified as a new group of Ser-Thr kinases in the human kinome diverging very early from the same branch that led to casein kinase I (CK1) (Manning et al. 2002). This family has only one ortholog gene in invertebrates, such as C. elegans and Drosophila melanogaster, and is not present in yeast (Klerkx et al. 2009).

VRK2 Gene and Expression

The human VRK2 gene is located in chromosome 2p16.1 and generates two messages by alternative splicing. Their translation generates two protein isoforms, VRK2A (also known as VRK2) and VRK2B. The VRK2A corresponds to the full-length protein and is expressed from a message of 1833 nucleotides coding for a protein of 508 amino acids. The alternatively spliced variant includes a novel exon and generates a message of 1877 nucleotides. The additional exon has 44 nucleotides and is the new exon 13. The message for isoform B has an in-frame termination codon, generating a shorter protein of 397 amino acids that is truncated and lacks the C-terminal region that is present in isoform A (Nichols and Traktman 2004; Blanco et al. 2006). Isoform VRK2B detected is dispersed in cytoplasm and nuclei. VRK2B is likely to compensate nuclear VRK1 functions in those cells with low levels of VRK1 protein (Blanco et al. 2006), since both have similar substrate specificity (Sanz-Garcia et al. 2011). The murine VRK2 is similar to the human gene, but no alternatively spliced coding variant has been identified (Nichols and Traktman 2004).

Human VRK2 RNA is detected in all tissues, and the level is higher in those with high proliferation activity such as tumor cell lines. Fetal tissues express higher levels than adult organs (Nezu et al. 1997; Nichols and Traktman 2004).VRK2A has been detected in all cell types examined, whereas VRK2B has only been detected in cells in which VRK1 expressed at low levels or is cytoplasmic. Therefore, nuclear VRK2B might be functionally redundant with VRK1 in some roles not yet identified (Blanco et al. 2006).

During hematopoietic development in murine embryos, the highest level of VRK2 expression is achieved at days E11.5–E13.5, in thymus, spleen, and liver, at a time of massive hematopoietic-liver expansion (Vega et al. 2003). Expression increases again at day 17.5, just before delivery. In adult mice, high RNA levels are present in liver, kidney, and muscle (Vega et al. 2003).

VRK2 Protein Structure and Subcellular Localization

The amino acid sequence of human VRK2 is slightly different from other VRK kinases and contains amino acid substitutions in several key residues, but it is still catalytically active (Nichols and Traktman 2004) (Blanco et al. 2006). The crystal structure of the catalytic domain of human VRK2 (PDB: 2V62) has been determined and it differs in the activation segment from the catalytically inactive VRK3 (Scheeff et al. 2009). VRK2A and VRK2B proteins have a strong autophosphorylation activity in multiple residues (Nichols and Traktman 2004; Blanco et al. 2006). However, both VRK2 proteins are also likely to be regulated and be the target of other kinases not yet identified. The C-terminal region is very different between VRK2A and VRK2B. VRK2A is the normal full-length protein and has 508 amino acids. VRK2A has a conserved BAB (basic-acid-basic motif) of unknown function in its C-terminal region, and the last amino acids are hydrophobic and form a typical transmembrane anchoring region. VRK2B is the result of alternative splicing in some cells and has 397 residues, of which the first 394 are identical to the corresponding region in VRK2A (Fig. 1), and its last three residues are different (VEA), thus it lacks most of the C-terminal region present in VRK2A. Neither isoform has a nuclear localization signal. Several proteins have been identified interacting with different regions of VRK2A or VRK2B (Fig. 1).
VRK2, Fig. 1

Structure of human VRK2A and VRK2B isoforms and their protein interactions. ATP (position of ATP binding site). Catalytic site is indicated. BAB basic-acid-basic region, TM transmembrane region, VEA three terminal amino acids in VRK2B isoform, which are different from VRK2A. The interacting proteins and the location of the regions of interaction with other proteins are also indicated (right image). Some of the interactions are common to both isoforms

The human VRK2A protein is located in the endoplasmic reticulum (ER), partly in the perinuclear area (Nichols and Traktman 2004). The VRK2A isoform has a hydrophobic membrane-anchoring domain that is not present in isoform VRK2B. VRK2A localizes to endoplasmic reticulum (ER) membranes and colocalizes with calnexin and calreticulin, two ER markers, and is the isoform present in all cell types (Nichols and Traktman 2004; Blanco et al. 2006). VRK2A also colocalizes with mitochondria, as detected by its colocalization with the Mitotracker reagent (Blanco et al. 2006). VRK2B lacks the C-terminal region and its transmembrane hydrophobic tail, thus it is not bound to membranes. Thus VRK2B isoform is detected as granular deposits in both cytoplasm and nucleus, and its expression is restricted to some cells by unknown reasons, but it is a regulated expression (Blanco et al. 2006).

VRK2 Phosphorylation Substrates and Protein Interactions

The two VRK2 isoforms, which differ in their subcellular location, seem to have similar substrate specificity in vitro. VRK2A and VRK2 kinase activity have a similar specificity in the phosphorylation of peptides in vitro. The two VRK2 isoforms prefer basic sequences and their pattern of phosphorylation is similar to that of VRK1 (Sanz-Garcia et al. 2011). Therefore, in vivo specificity is likely to be determined by subcellular localization of the kinase and local substrate availability.

Both VRK2A and VRK2B phosphorylate human TP53 at Thr18 (equivalent to mouse Thr21) (Blanco et al. 2006). It is not known if the mitochondrial VRK2A phosphorylates mitochondrial p53.

VRK2A both murine and human as well as VRK1 are able to phosphorylate the N-terminal region of BAF, a small protein that interacts with DNA, and is required for nuclear envelope assembly. Phosphorylation of BAF by VRK1 results in loss of binding to DNA and inhibits nuclear envelope assembly (Nichols et al. 2006). VRK2, like VRK1, is also able to phosphorylate the amino terminus of BAF (barrier to autointegration factor) protein, which is required for assembly of the nuclear envelope, and also causes the loss of BAF binding to DNA (Nichols et al. 2006). The unique C. elegans ortholog for the VRK family, Vrk1–1, also phosphorylates Baf (Gorjanacz et al. 2008). This BAF phosphorylation impairs the formation of retroviral MoMLV (Moloney-murine leukemia virus) integration complexes (Suzuki et al. 2010).

VRK2A phosphorylates the JIP1 scaffold protein, but its significance is unknown since its effects on MAPK signaling are independent of phosphorylation and only requires the protein interaction (Blanco et al. 2007; Blanco et al. 2008).

The autophosphorylation activity of both VRK2 proteins can be inhibited in vitro by a stable interaction between the small nuclear GTPase Ran in a nucleotide-free or GDP-bound conformation. The GTP-bound form of Ran has no apparent effect on VRK2 kinase activity (Sanz-Garcia et al. 2008). The asymmetric distribution of RAN-GDP and RAN-GTP in cells might thus reflect a differential kinase activity depending on their localization. VRK2A has a membrane targeting domain that allows VRK2A to localize to intracellular membranes in the endoplasmic reticulum and mitochondria. VRK2B lacks this domain.

The large carboxy-terminal region of VRK2A can interact with other proteins, such as the JIP1 (Jun amino-terminal kinase (JNK)-interacting protein 1) (Blanco et al. 2007; Blanco et al. 2008) and KSR1 scaffold proteins (Fernandez et al. 2010), and thus inhibits signal transduction, but they interact in a different manner. In these complexes VRK2A also directly interacts with different mitogen associated protein kinases, such as MEK1 (Fernandez et al. 2010) and TAK1 (Blanco et al. 2007; Blanco et al. 2008). Binding of VRK2 to JIP1 prevents the incorporation of JKN to the complexes and thus there is no activation of transcription (Fig. 2).
VRK2, Fig. 2

Inhibition of MAPK signaling by the interaction of VRK2A with scaffold proteins such as JIP1 and KSR1 (Blanco et al. 2008). ER endoplasmic reticulum

VRK2A also directly interacts with the scaffold KSR1, implicated in signal transmission from EGF, ERBB2, KRAS, and BRAF signals that activate AP1-dependent transcription (Fernandez et al. 2010). In this complex VRK2 also directly interacts with MEK1 (Fernandez et al. 2010).

The C-terminal region of VRK2A interacts with an Epstein-Barr Virus (EBV) protein, BHRF1, which is a homolog of BCL2 and enhances cell survival, but no interaction with human BCL2 has been detected (Li et al. 2006).

VRK2 Modulates MAPK Signaling

VRK2A isoform modulates signaling mediated by MAPK pathways. This action is mediated by a direct interaction between a scaffold protein and VRK2A, and does not depend on its kinase activity. Stress responses, such as hypoxia (Blanco et al. 2007), and response to inflammatory cytokines, such as interleukin-1β (IL-1β) (Blanco et al. 2008), mediate signals by the activation of Jun dependent transcription. These responses are inhibited by VRK2A which forms a macromolecular complex, signalosome, which is anchored to endoplasmic reticulum membranes. In this complex VRK2A interacts with TAK1, the first MAP kinase (MAPKKK) and the JIP1 scaffold protein (Blanco et al. 2007; Blanco et al. 2008). This complex prevents the incorporation of JNK (c-Jun N-terminal kinase), which cannot be activated by phosphorylation, inhibiting c-Jun dependent transcription. The amount of VRK2A in the cells seems to control the fraction of JIP1 free and bound, thus creating a compartmentalization with two complexes, one active without VRK2A, and another inactive with VRK2 (Fig. 2).

Many proliferative responses mediated by oncogenes are transmitted by MAPK complexes resulting in the activation of RAF-MEK-ERK pathway, which is assembled on the KSR1 scaffold protein (Fig. 2). Among the activated oncogenes that can be modulated by VRK2A are ERBB2, RAS, and RAF. VRK2A directly interacts with MEK1 and KSR1 preventing the activation of ERK1 and p90RSK (Fernandez et al. 2010). VRK2A does not affect signals that partly use this pathway, such as AKT. In this way, VRK2A inhibits at a downstream level the signal initiated in ERBB2, which is amplified in many tumors types. Also reduced level of P-ERK was observed in the presence of VRK2, and VRK3, in the analysis of the EGFR response pathway (Komurov et al. 2010).

VRK2 Regulates Cell Invasion by Controlling Cox2 Expression

VRK2 can control tumor cell invasion in part by regulating the gene expression of COX2 (cyclooxygenase-2). This effect of VRK2 on cell invasiveness is mediated by a direct phosphorylation of the NFAT1 (nuclear factor of activated T cells) transcription factor in Ser-32 by VRK2. The COX2 gene proximal promoter ha an NFAT1 target sequence (Vazquez-Cedeira and Lazo 2012). The treatment of tumor cells with phorbol esters that induce a similar phosphorylation of NFAT1 and activation of COX2 gene expression that facilitates cell invasion (Vazquez-Cedeira and Lazo 2012). Knockdown of vrk2 reduces invasion by MDA-MB-231 and MDA-MB-435 tumors cells induced by phorbol esters and ionomycin treatment (Vazquez-Cedeira and Lazo 2012).

VRK2 Regulates the Intrinsic Pathway of Apoptosis

VRK2A regulates the intrinsic pathway of apoptosis by directly interacting in mitochondria with Bcl-xL, but not with Bcl-2, Bax, Bad, PUMA, or Binp-3L. Mechanistically VRK2A does not compete with Bax for interaction with Bcl-xL and the three proteins can form a protein complex (Monsalve et al. 2013). The presence VRK2A reduces the release of cytochrome C and prevents apoptosis. In addition VRK2 inhibits the expression of Bax gene expression, thus contributing to prevention of apoptosis by a second mechanism (Monsalve et al. 2013). The loss of VRK2A causes a release of cytochrome C, activation of caspases, PARP processing, and cell death (Monsalve et al. 2013) (Fig. 3).
VRK2, Fig. 3

VRK2 regulates the intrinsic pathway of apoptosis

Epstein-Barr virus (EBV) expresses the BHRF1 protein that is a homolog of mammalian Bcl2, which has a protective role and favors cell survival. BHRF1 interacts with the C-terminal region of VRK2A, and if VRK2A levels are high, cells are protected against apoptosis, and this protection depends on the interaction and not on the kinase activity of VRK2 (Li et al. 2006).

VRK2 Controls Chaperonins

Chaperonins are proteins controlling the correct folding of proteins and thus prevent pathological protein aggregation that causes neurodegenerative diseases. The chaperonin TRiC is an important regulator in the elimination of misfolded proteins. TRiC protein level is downregulated by VRK2 through the proteasome by recruiting the E3 ligase COP1 (Kim et al. 2014). In this context VRK2 phosphorylates the USP25, a deubiquitinase that interacts with TRiC, in Thr680, Thr727, and Ser745 residues causing the inactivation of USP25 deubiquitinase activity (Kim et al. 2015) and thus permitting protein degradation. By this mechanism, VRK2 can regulate the accumulation of neurpathogenic proteins with poly-Q expansions (>40) that form intracellular aggregates. High levels of VRK2 facilitate degradation of proteins such as huntingtin and thus reduces the formation of its poly-Q aggregates; and VRK2 depletion facilitates formation of huntingtin poly-Q aggregates (Kim et al. 2015). It is possible that a reduction of intracellular poly-Q aggregates in cells might be achieved if specific VRK2 inhibitors are designed. This will represent a leap forward in the control of neurodegenerative diseases associated to intracellular poly-Q aggregation.

VRK2 in Human Cancer: Breast Cancer and Glioblastomas

VRK2 levels in human breast cancer correlated positively with estrogen and progesterone receptors. VRK2 was inversely correlated with ErbB2, thus Erb2+ breast cancer have low levels of VRK2. VRK2 can block the signal mediated by MAPK in response to EGF or its receptors (ERBB family), as well as signals from mutated RAS or BRAF. By reducing VRK2 levels, the inhibition of MAPK pathway transcriptional signaling is partly removed in these tumors (Fernandez et al. 2010). This downstream inhibitory effect of VRK2A on MAPK can also be occurring in other tumors with mutations along this signaling pathway, but this needs to be demonstrated.

Expression of VRK2 has been studied in human primary astrocytomas (Rodriguez-Hernandez et al. 2013). High expression of VRK2, as well as VRK1, correlated with proliferation markers p63 or Ki67, but there was no correlation with p53. High levels of VRK2 identified a subgroup of high-grade astrocytomas that presented an improvement in survival using Kaplan-Meier and Cox models (Rodriguez-Hernandez et al. 2013). Overexpression of VRK2 in astrocytomas cell lines resulted in a reduction of its growth (Rodriguez-Hernandez et al. 2013). Thus the better prognosis of some astrocytomas might be a consequence of the downregulation of MAPK signaling by VRK2. Also high levels of VRK2 have been reported in colorectal adenocarcinomas (Hennig et al. 2012).

VRK2 in Viral Infections

VRK2 received its name from the homology of its catalytic domain and that of the unique vaccinia virus kinase B1, which is required for Vaccinia virus DNA replication early in infection. Despite their divergence, VRK2 and VRK1 are able to partially rescue the replication of vaccinia virus strains with defective B1 kinase (Boyle and Traktman 2004).

Targeting VRK2 with Kinase Inhibitors

Human vaccinia-related kinases (VRK1 and VRK2) are atypical active Ser-Thr kinases implicated in control of cell cycle entry, apoptosis, and autophagy, and affect signaling by mitogen activated protein kinases (MAPK). The specific structural differences in VRK catalytic sites make them suitable candidates for development of specific inhibitors. These two kinases have been tested for their sensitivity to inhibitors targeting other kinases such as Src, MEK1, B-Raf, JNK, p38, CK1, ATM, CHK1/2, and DNA-PK and most of them have no effect even at 100 micromolar. But despite the low sensitivity, some of these inhibitors in the low micromolar range are able to discriminate between VRK1 and VRK2. VRK2 is more sensitive to roscovitine, RO 31-8220, Cdk1 inhibitor, AZD7762, and IC261. VRK1 is more sensitive to staurosporine, RO 31-8220 and TDZD8 (Vazquez-Cedeira et al. 2011). In both cases some inhibition was achieved at doses unsuitable for clinical use. Thus, the two kinases present a different pattern of sensitivity to kinase inhibitors (Vazquez-Cedeira et al. 2011). This differential response to known inhibitors can provide a structural framework for VRK1 or VRK2 specific inhibitors with low or no cross-inhibition and high specificity (Fedorov et al. 2007).

VRK2 in Neurological and Psychiatric Diseases

Several polymorphisms with the VRK2 loci on chromosome 2p16.1, but outside the coding region, have been identified in several studies as associated to predisposition several neurological and psychiatric disorders such as epilepsy (Epilepsies. ILARCoC 2014), bipolar disorders (Kerner et al. 2013), and schizophrenia (Irish Schizophrenia Genomics Consortium and the Wellcome Trust Case Control Consortium 2012; Tesli et al. 2016). The role of VRK2 as regulator MAPK signaling pathways might explain this VRK2 role, since MAPK pathways are targets of drugs used in these diseases such as valproic acid, lithium, or antidepressants.


VRK2 is a Ser-Thr kinase and has two isoforms, cytosolic and nuclear. The full-length VRK2 cytosolic isoform (A) inhibits MAPK signaling by a direct interaction with the corresponding JIP1 or KSR1 scaffold proteins. As a consequence high levels of VRK2A inhibits in a dose dependent manner signals mediated by the TAK1-MKK7-JNK in response to hypoxia or interleukin, and the signal of the ERBB2-RAS-RAF-MEK-ERK pathway. Downregulation of VRK2A relieves this inhibition and allows signal transmission in response to stimuli initiated in Receptor-tyrosine kinases (RTK), such as ERBB2. Thus, in breast cancer, VRK2A and ERBB2 present an inverse correlation. VRK2 controls protein quality by regulating degradation of misfolded proteins. Mitochondrial VRK2 controls the association of Bax to mitochondrial membranes and thus modulates apoptosis. Allelic noncoding polymorphisms of the VRK2 gene have been linked to several neurological diseases.


  1. Blanco S, Klimcakova L, Vega FM, Lazo PA. The subcellular localization of vaccinia-related kinase-2 (VRK2) isoforms determines their different effect on p53 stability in tumour cell lines. Febs J. 2006;273:2487–504. doi: 10.1111/j.1742-4658.2006.05256.x.PubMedCrossRefGoogle Scholar
  2. Blanco S, Santos C, Lazo PA. Vaccinia-related kinase 2 modulates the stress response to hypoxia mediated by TAK1. Mol Cell Biol. 2007;27:7273–83. doi: 10.1128/MCB.00025-07.PubMedPubMedCentralCrossRefGoogle Scholar
  3. Blanco S, Sanz-Garcia M, Santos CR, Lazo PA. Modulation of interleukin-1 transcriptional response by the interaction between VRK2 and the JIP1 scaffold protein. PLoS One. 2008;3:e1660. doi: 10.1371/journal.pone.0001660.PubMedPubMedCentralCrossRefGoogle Scholar
  4. Boyle KA, Traktman P. Members of a novel family of mammalian protein kinases complement the DNA-negative phenotype of a vaccinia virus ts mutant defective in the B1 kinase. J Virol. 2004;78:1992–2005. doi: 10.1128/JVI.78.4.1992-2005.2004PubMedPubMedCentralCrossRefGoogle Scholar
  5. Epilepsies. ILAECoC. Genetic determinants of common epilepsies: a meta-analysis of genome-wide association studies. Lancet Neurol. 2014;13:893–903. doi: 10.1016/S1474-4422(14)70171-1.
  6. Fedorov O, Marsden B, Pogacic V, Rellos P, Muller S, Bullock AN, et al. A systematic interaction map of validated kinase inhibitors with Ser/Thr kinases. Proc Natl Acad Sci U S A. 2007;104:20523–8. doi: 10.1073/pnas.0708800104.PubMedPubMedCentralCrossRefGoogle Scholar
  7. Fernandez IF, Blanco S, Lozano J, Lazo PA. VRK2 inhibits mitogen-activated protein kinase signaling and inversely correlates with ErbB2 in human breast cancer. Mol Cell Biol. 2010;30:4687–97. doi: 10.1128/MCB.01581-09.PubMedPubMedCentralCrossRefGoogle Scholar
  8. Gorjanacz M, Klerkx EP, Galy V, Santarella R, Lopez-Iglesias C, Askjaer P, et al. Caenorhabditis elegans BAF-1 and its kinase VRK-1 participate directly in post-mitotic nuclear envelope assembly. EMBO J. 2008;26:132–43. doi: 10.1038/sj.emboj.7601470.CrossRefGoogle Scholar
  9. Hennig EE, Mikula M, Rubel T, Dadlez M, Ostrowski J. Comparative kinome analysis to identify putative colon tumor biomarkers. J Mol Med. 2012;90:447–56. doi: 10.1007/s00109-011-0831-6.PubMedCrossRefGoogle Scholar
  10. Irish Schizophrenia Genomics Consortium, the Wellcome Trust Case Control Consortium. Genome-wide association study implicates HLA-C*01:02 as a risk factor at the major histocompatibility complex locus in schizophrenia. Biol Psychiatry. 2012; doi: 10.1016/j.biopsych.2012.05.035.Google Scholar
  11. Kerner B, Rao AR, Christensen B, Dandekar S, Yourshaw M, Nelson SF. Rare genomic variants link bipolar disorder with anxiety disorders to creb-regulated intracellular signaling pathways. Front Psychol. 2013;4:154. doi: 10.3389/fpsyt.2013.00154.Google Scholar
  12. Kim S, Lee D, Lee J, Song H, Kim HJ, Kim KT. VRK2 controls the stability of the eukaryotic chaperonin TRiC/CCT by inhibiting the deubiquitinating enzyme USP25. Mol Cell Biol. 2015; doi: 10.1128/MCB.01325-14.Google Scholar
  13. Kim S, Park DY, Lee D, Kim W, Jeong YH, Lee J, et al. Vaccinia-related kinase 2 mediates accumulation of polyglutamine aggregates via negative regulation of the chaperonin TRiC. Mol Cell Biol. 2014;34:643–52. doi: 10.1128/MCB.00756-13.PubMedPubMedCentralCrossRefGoogle Scholar
  14. Klerkx EP, Lazo PA, Askjaer P. Emerging biological functions of the vaccinia-related kinase (VRK) family. Histol Histopathol. 2009;24:749–59. doi:  10.14670/HH-24.749PubMedGoogle Scholar
  15. Komurov K, Padron D, Cheng T, Roth M, Rosenblatt KP, White MA. Comprehensive mapping of the human kinome to epidermal growth factor receptor signaling. J Biol Chem. 2010;285:21134–42. doi: 10.1074/jbc.M110.137828.PubMedPubMedCentralCrossRefGoogle Scholar
  16. Li LY, Liu MY, Shih HM, Tsai CH, Chen JY. Human cellular protein VRK2 interacts specifically with Epstein-Barr virus BHRF1, a homologue of Bcl-2, and enhances cell survival. J Gen Virol. 2006;87:2869–78. doi:  10.1099/vir.0.81953-0PubMedCrossRefGoogle Scholar
  17. Manning G, Whyte DB, Martinez R, Hunter T, Sudarsanam S. The protein kinase complement of the human genome. Science. 2002;298:1912–34. doi: 10.1126/science.1075762.PubMedCrossRefGoogle Scholar
  18. Monsalve DM, Merced T, Fernandez IF, Blanco S, Vazquez-Cedeira M, Lazo PA. Human VRK2 modulates apoptosis by interaction with Bcl-xL and regulation of BAX gene expression. Cell Death Dis. 2013;4:e513. doi: 10.1038/cddis.2013.40.PubMedPubMedCentralCrossRefGoogle Scholar
  19. Nezu J, Oku A, Jones MH, Shimane M. Identification of two novel human putative serine/threonine kinases, VRK1 and VRK2, with structural similarity to vaccinia virus B1R kinase. Genomics. 1997;45:327–31. doi:  10.1006/geno.1997.4938PubMedCrossRefGoogle Scholar
  20. Nichols RJ, Traktman P. Characterization of three paralogous members of the mammalian vaccinia related kinase family. J Biol Chem. 2004;279:7934–46. doi:  10.1074/jbc.M310813200PubMedCrossRefGoogle Scholar
  21. Nichols RJ, Wiebe MS, Traktman P. The vaccinia-related kinases phosphorylate the N′ terminus of BAF, regulating its interaction with DNA and its retention in the nucleus. Mol Biol Cell. 2006;17:2451–64. doi: 10.1091/mbc.E05-12-1179.PubMedPubMedCentralCrossRefGoogle Scholar
  22. Rodriguez-Hernandez I, Vazquez-Cedeira M, Santos-Briz A, Garcia JL, Fernandez IF, Gomez-Moreta JA, et al. VRK2 identifies a subgroup of primary high-grade astrocytomas with a better prognosis. BMC Clin Pathol. 2013;13:23. doi: 10.1186/1472-6890-13-23.PubMedPubMedCentralCrossRefGoogle Scholar
  23. Sanz-Garcia M, Lopez-Sanchez I, Lazo PA. Proteomics identification of nuclear Ran GTPase as an inhibitor of human VRK1 and VRK2 (vaccinia-related kinase) activities. Mol Cell Proteomics. 2008;7:2199–214. doi: 10.1074/mcp.M700586-MCP200.PubMedPubMedCentralCrossRefGoogle Scholar
  24. Sanz-Garcia M, Vazquez-Cedeira M, Kellerman E, Renbaum P, Levy-Lahad E, Lazo PA. Substrate profiling of human vaccinia-related kinases identifies coilin, a Cajal body nuclear protein, as a phosphorylation target with neurological implications. J Proteome. 2011;75:548–60. doi: 10.1016/j.jprot.2011.08.019.CrossRefGoogle Scholar
  25. Scheeff ED, Eswaran J, Bunkoczi G, Knapp S, Manning G. Structure of the pseudokinase VRK3 reveals a degraded catalytic site, a highly conserved kinase fold, and a putative regulatory binding site. Structure. 2009;17:128–38. doi: 10.1016/j.str.2008.10.018.PubMedPubMedCentralCrossRefGoogle Scholar
  26. Suzuki Y, Ogawa K, Koyanagi Y. Functional disruption of the moloney murine leukemia virus preintegration complex by vaccinia-related kinases. J Biol Chem. 2010;285:24032–43. doi: 10.1074/jbc.M110.116640.PubMedPubMedCentralCrossRefGoogle Scholar
  27. Tesli M, Wirgenes KV, Hughes T, Bettella F, Athanasiu L, Hoseth ES, et al. VRK2 gene expression in schizophrenia, bipolar disorder and healthy controls. Br J Psychiatry. 2016; doi: 10.1192/bjp.bp.115.161950.PubMedGoogle Scholar
  28. Vazquez-Cedeira M, Barcia-Sanjurjo I, Sanz-Garcia M, Barcia R, Lazo PA. Differential inhibitor sensitivity between human kinases VRK1 and VRK2. PLoS One. 2011;6:e23235. doi: 10.1371/journal.pone.0023235.PubMedPubMedCentralCrossRefGoogle Scholar
  29. Vazquez-Cedeira M, Lazo PA. Human VRK2 (vaccinia-related kinase 2) modulates tumor cell invasion by hyperactivation of NFAT1 and expression of cyclooxygenase-2. J Biol Chem. 2012;287:42739–50. doi: 10.1074/jbc.M112.404285.PubMedPubMedCentralCrossRefGoogle Scholar
  30. Vega FM, Gonzalo P, Gaspar ML, Lazo PA. Expression of the VRK (vaccinia-related kinase) gene family of p53 regulators in murine hematopoietic development. FEBS Lett. 2003;544:176–80. doi:  10.1016/S0014-5793(03)00501-5.PubMedCrossRefGoogle Scholar

Copyright information

© Springer International Publishing AG 2018

Authors and Affiliations

  1. 1.Instituto de Biología Molecular y Celular del Cáncer, Centro de Investigación del CáncerConsejo Superior de Investigaciones Científicas (CSIC)-Universidad de SalamancaSalamancaSpain
  2. 2.Instituto de Biología Molecular y Celular del Cáncer, Consejo Superior de Investigaciones Científicas (CSIC)-Universidad de SalamancaSalamancaSpain
  3. 3.Instituto de Investigación Biomédica de Salamanca (IBSAL)Hospital Universitario de SalamancaSalamancaSpain